[1] 2021 Guidelines for Cardiovascular Disease Prevention in ESC Clinical Practice

★Prepare hyperlipidemia in order

People without ASCVD, diabetes, chronic kidney disease or familial hypercholesterolemia

→ Risk classification according to risk group, age, blood pressure, gender and non-HDL-C by country

→ Risk classification according to risk group, age, blood pressure, gender and non-HDL-C by country

Aeon-fast measurement of Lipid parameters are recommended by general population screening inspection.The pre-value is expected to be a fast time.Note that the metadata is required for c-L-C analysis, diabetes, diabetes, high neutron fat blood disease, diabetes, high neutron fat blood. ■ A DL-C is directly measured, but the following.

Such calculations are reasonable when the neutral fat is less than 400 and less than 400 and LDL-C is not accurate.If DL-C is very low, use other official fat blood pressure, or higher neutron fat blood cells, or the L-C. ■ Apple ipoprotini B is especially a direct estimate value of the Intel Logenic lipid pid pid pid pid pid pid pid pid pid pid pid pid p.However, information that the policy provides similar to c-L-LC.

■ The NON-HDL cholesterol, but not requesting HDL cholesterol, but not requesting less than high neutral fat blood cells mentioned in L-C.This is accurate and it is also accurate, and it seems that it’s not hungry. We suggest it as a reasonable alternative treatment goal for all patients, particularly for those with hypertriglyceridaemia or DM.

■ A lifetime treatment gain of L-C reduction in health adults can help you to consultation.The following is the average period (y Search) gain of the average period (y Search-C in the basis of the CVD to 40 percentage of the show-moduletreme Count. ■ This guidelines recommendations to recommend the step-to-C prefixes and higher treatment levels are lower than previous 2016 ESC target.If the ASCVD or the recovery host is the target for the recovery host. ■ If you experience ASCVDs within two years, it can also consider the 40 mg/dL.The difference of treatment gain is not changed depending on whether or not the age of diabetes.REF. 1. Cardiovascular Disease Prevention Guidelines in the European Heart Journal (2021) 42, 3227-3337, 2021 ESC Clinical Practice 2. 2022 송파구의사회 추계 온라인 학술대회